Arcus Biosciences is a clinical-stage company developing casdatifan, a pill that blocks HIF-2α, for kidney cancer, and quemliclustat for pancreatic cancer; neither is approved.
Arcus's case centers on investigational casdatifan for clear cell kidney cancer, with encouraging activity awaiting randomized confirmation. PEAK-1 enrollment is targeted for year-end 2026 and PEAK-20 initiation for the fourth quarter of 2026. Quemliclustat's PRISM-1 results are expected in the first half of 2027; immunology offers earlier-stage opportunities. Management guides to runway until at least the second half of 2028. The completed offering added approximately $269.7 million net, strengthening funding while diluting ownership.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Cash lasts until at least 2H 2028
Will the added cash extend funding flexibility or be absorbed by expanded development spending?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Casdatifan leads Arcus's case; completed equity raise strengthens funding while diluting ownership
Three Phase 3 failures end Gilead collaboration; quemliclustat pancreatic Phase 3 is sole near-term binary, ~$130M quarterly burn
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Gastrointestinal cancers, Other cancers, Neurology and pain, Lung and respiratory diseases, Liver and digestive diseases, Skin diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
11 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.